Venlo

• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol … Recruiting
  2023-506698-36-00 5 2024-02-02 low-volume metastatic castration-sensitive prostate cancer
• A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1 … Recruiting
  2023-508543-42-00 1 2024-01-22 Chronic heart failure
• Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Recruiting
  2024-518844-20-00 10 2023-10-03 Treatment of Acute Gout Flare
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• Combination therapy of 5-Fluorouracil and Calcipotriol versus 5-Fluorouracil in the treatment of Actinic Keratosis: a multicentre randomized … Ended recruitment
  2024-511409-42-00 6 2024-09-02 Actinic Keratosis
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended recruitment
  2022-502664-21-00 6 2023-05-01 multiple sclerosis
• SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat … Ended recruitment
  2024-514965-20-00 4 2022-06-02 Breast cancer
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended recruitment
  2024-516205-23-00 4 2019-04-09 Breast cancer
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended recruitment
  2024-516204-42-00 5 2017-11-21 Breast cancer

Showing 25–48 of 61 trials